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Introduction
Although significant numbers of prostate cancer (PCa) 
patients become depressed (Bill-Axelson et al., 2011; 
Johansson et al., 2011; Kunkel, Bakker, Myers, Oyesanmi, 
& Gomella, 2000) and experience higher rates of admis-
sion to emergency treatment, hospitalization, outpatient 
visits, and death (Jayadevappa, Malkowicz, Chhatre, 
Johnson, & Gallo, 2011), two recent reviews of interven-
tions used to reduce this depression reported only par-
tially supportive results for those interventions. Newby, 
Graff, Ganzani, and McDonagh (2015) applied meta-
analysis to data from nine studies that used exercise, infor-
mation, psychotherapy, and peer support as treatment for 
depression among PCa patients and not only reported an 
overall significant reduction in depression but also noted 
that only one of the nine studies reported a statistically 
significant improvement in patients’ depression scores. In 
their systematic review of 14 randomized control studies 
of interventions to relieve anxiety and depression among 
PCa patients, Chien, Liu, Chien, and Liu (2014) reported 
that psychosocial strategies significantly reduced depres-
sion in these patients but only for a period of 3 months 
after treatment.
Although the most commonly used classification for 
depression, the diagnostic criteria for major depressive 
disorder (MDD) set out in the fifth edition of the 
Diagnostic and Statistical Manual for Mental Disorders 
(DSM-5; APA, 2013) may not be completely valid when 
measuring depression in men because men may exhibit 
additional symptoms of depression, as demonstrated by 
the Gotland Study of the effects of general practitioner 
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Abstract
Up to a quarter of all prostate cancer (PCa) patients suffer from clinically significant depression but treatments are 
inconsistent and short-lived in their efficacy. One possible reason could be that “male depression” is not adequately 
diagnosed by the criteria for major depressive disorder (MDD) used in many clinical settings. In response to this 
limitation, the Gotland Scale of Male Depression (GSMD) was developed to identify the extra symptoms of MDD in 
men. Although the factor structure of the GSMD has been reported in non-PCa samples, it has not been determined 
for this group of men. Two samples of PCa patients were recruited, 191 from Australia and 138 from the United 
Kingdom and all patients received the GSMD individually, plus a background questionnaire. Two-factor solutions were 
identified for each of the two samples. The Australian sample was characterized by changes in emotional and somatic 
function, followed by depressed mood. The U.K. sample exhibited the same two-factor solution but in reverse order 
of weighting. Targeted treatments for depression in PCa patients may benefit from identification of the loadings that 
individual patients have on these two GSMD factors so that specific clinical profiles and treatment needs may be based 
on this information about their depression.
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educational training on suicide rates (Rutz, von Knorring, 
Pihlgren, Rihmer, & Walinder, 1995). In the Gotland 
Study, the overall suicide rate decreased by 60% after 
general practitioners had been trained to recognize the 
symptoms of MDD but that change in suicide rate was 
due to decreases in the female suicide rate but not in the 
male suicide rate. Rutz et al. (1995) argued that this was 
due to the underdiagnosis of men who were depressed but 
not easily identifiable via MDD symptomatology alone 
and that extra symptoms of depression were needed when 
measuring depression in males (Innamorati et al., 2011; 
Rutz et al., 1995; Zierau, Bille, Rutz, & Bech, 2002), 
including aggression, irritability and alcohol use, none of 
which are included in the diagnostic criteria for MDD 
(APA, 2013).
If this “male depression” hypothesis is true, then it 
may at least partially account for the inconsistent and 
overall limited effectiveness of the interventions reviewed 
by Newby et al. (2015) and Chien et al. (2014) because 
“true” male depression in PCa patients may not have been 
reliably assessed by the instruments used in the studies 
examined in those reviews. Some supporting evidence 
for this argument comes from a previous study which 
assessed the prevalence of depression via the Gotland 
Scale for Male Depression (GSMD; Sharpley, Bitsika, & 
Christie, 2014), which was developed to identify and 
assess the severity of MDD plus symptoms of male 
depression. In that study, about 24% of the PCa patients 
who were identified as depressed on the GSMD would 
not have been similarly identified by the application of 
the diagnostic criteria for MDD alone (Sharpley, Bitsika, 
& Christie, 2014).
However, depression is not a unitary construct, with at 
least 1,497 possible combinations for MDD (Ostergaard, 
Jensen, & Bech, 2011), adding impetus to the call for 
individualized assessment and treatment of depression 
(Insel, 2013), and it may be that male depression as mea-
sured by the GSMD is similarly multidimensional in its 
structure. Several previous studies of the GSMD have 
explored its underlying factor structure in an attempt to 
further describe the underlying structure of the male 
depression construct. Innamorati et al. (2011) examined 
the GSMD factor structure in 152 male psychiatric inpa-
tients and reported a single-factor solution, as did Chu 
et al. (2014) with 231 male outpatients from a polyclinic, 
but no previous reports have been made of the factor 
structure of the GSMD in PCa patients. Because this 
information may help identify aspects of the GSMD that 
can be targeted for specific treatment options, thus poten-
tially increasing the efficacy of therapy for depression in 
PCa patients, this study explored the factor structure of 
the GSMD in PCa patients. To enhance the generalizabil-
ity of the findings, two samples were recruited, each from 
a different nation and data from each were examined 
separately and then compared for their overall results in 
order to emphasize any national differences that may 
occur.
Method
Subjects
A total of 329 men with PCa were recruited, 191 (58.0%) 
from the Gold Coast, Australia and 138 (42.0%) from 
London, United Kingdom. All were volunteers and were 
attending outpatient clinics. They were recruited by 
administration staff, cancer nurses, radiologists, or oncol-
ogists either while waiting for treatment or via a tele-
phone and postal survey.
Materials
Demographic Questionnaire. A background questionnaire 
about participants’ ages, living situation, time since diag-
nosis, present status of their PCa and past and present 
treatments. Although there are several possible hormone 
treatments, some of which may vary in their effects, this 
variable was aggregated here due to the small number of 
patients who were receiving some specific hormone 
treatments.
Male Depression. GSMD was developed by Rutz and col-
leagues (1995) to improve recognition of depression in 
males. The GSMD has satisfactory validity against the 
Major Depression Inventory and internal consistency 
(Cronbach’s alpha) of .86 (Zierau et al., 2002). Respon-
dents to the GSMD are asked to indicate “if your behav-
iour has changed during the last two weeks” in any of 13 
directions, each of which is measured by a single GSMD 
item, and to rate the intensity of their responses as “Not at 
all,” “ To some extent,” “Very true,” and “Extremely so.” 
The GSMD is composed of two subscales, one which 
assesses distress (seven items) and one which assesses 
depression (six items). Although five of the six depres-
sion items match DSM-5 criteria for MDD, the final item 
asks about the respondent’s family’s “tendency towards 
abuse, depression/dejection, suicide attempts” rather than 
about the respondent himself. Scores on the GSMD range 
from 0 to 39 and may be broken down into: 0 to 12 = no 
depression, 13 to 26 = probable depression, and 27 to 
39 = definite depression requiring treatment (Zierau 
et al., 2002).
Statistical Analysis
Data were analyzed via SPSS 22.0. Descriptive data were 
calculated and reliability of the GSMD assessed. 
Correlation coefficients were calculated to investigate the 
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associations between the demographic variables and 
GSMD scores; multivariate analysis of variance was used 
to test for the presence of significant differences in age, 
time since diagnosis, and GSMD score across the two 
samples. Exploratory factor analysis was conducted to 
determine the underlying structure of the GSMD across 
each sample. Principal components analysis was used in 
the identification of item clusters and factor loadings gen-
erated using both orthogonal and oblique rotations to 
determine the most coherent and interpretable solution.
Results
Characteristics of Study Participants
The demographic and GSMD characteristics of the two 
samples are reported in Table 1. Internal consistency 
(Cronbach’s alpha) for the GSMD was satisfactory for 
the Australian (.875) and U.K. (.851) samples and the 
deletion of no GSMD item would have increased these 
values by more than 2.0%, therefore all GSMD items 
were included at this stage of the analysis. The only signifi-
cant correlation between any of the demographic variables 
and the GSMD total score was for age (Australian sample, 
r = −.227, p < .01; U.K. sample, r = −.225, p < .01), indi-
cating that male depression significantly decreased with 
age across both samples, as in some other data (Henderson 
et al., 1998). The Australian patients had received their 
PCa diagnoses a significantly longer time than the U.K. 
sample (Table 1) but this was not significantly associated 
with the GSMD total scores. The relative proportions of 
samples that scored in the three depression categories for 
the GSMD are reported in Table 1.
Factor Analysis
Australian Sample. There were many interitem correlations 
greater than .3 between the GSMD Items 1 to 12 but none 
for GSMD Item 13, which was therefore deleted from the 
rest of this factor analysis (as Innamorati et al., 2011, also 
did for the same reason). Kaiser and Rice’s (Kaiser, 1974) 
Kaiser–Meyer–Olkin (KMO) measure of sampling ade-
quacy was 0.878 and Bartlett’s test of sphericity was sig-
nificant (χ2 = 1241.31, p < .001), thus justifying factor 
analysis with these data (Tabachnik & Fidell, 2007). 
Principal components extraction revealed two factors with 
Table 1. Demographic and Gotland Scale of Male Depression (GSMD) Data for Two Samples.
Variable Australian sample U.K. sample F p
Mean age, years 69.59 70.22 0.664 .416
Living situation (%)
 With wife/partner 87.8 82.6  
 Widowed 2.1 4.3  
 Divorced/separated 4.8 8.0  
 Never married 5.3 5.1  
Mean time since diagnosis, months 26.99 19.32 5.819 .016
Present cancer status (%)
 Still present 25.3 60.1  
 Remission 68.8 28.2  
 Recurring 5.9 11.6  
Past treatment (%)
 Radiotherapy 16.6 27.5  
 Surgery 7.5 8.7  
 Hormone 3.7 9.4  
 Combinations 58.9 54.4  
 None 13.4 0.0  
Current treatment (%)
 Radiotherapy 2.7 14.5  
 Surgery 0.0 0.0  
 Hormone 21.4 25.4  
 Combinations 3.7 60.1  
 None 72.2 0.0  
GSMD, mean (SD) 4.575 (5.490) 4.93 (5.03) 0.304 .582
GSMD categories (%)
 No depression 89.0 92.0  
 Probable depression 11.0 8.0  
 Requiring treatment 0.0 0.0  
Sharpley et al. 173
eigenvalues greater than 1.0, verified by inspection of the 
scree plot and parallel analysis. These two factors 
accounted for 59.19% of the variance (Factor 1 had an 
eigenvalue of 6.025 and accounted for 50.206% of the 
variance, Factor 2 had an eigenvalue of 1.079 and 
accounted for 8.988% of the variance). Oblimin rotation 
confirmed this two-factor solution.
U.K. Sample. Again, GSMD Item 13 did not correlate 
strongly with the remaining 13 items and was deleted 
from further analysis. There were multiple interitem cor-
relations in excess of .3 among the remaining 12 GSMD 
items, the KMO was 0.855, and Bartlett’s test of spheric-
ity was significant (χ2 = 704.501, p < .001). There were 
two factors with eigenvalues greater than 1.0, verified by 
the scree plot and parallel analysis. These two factors 
accounted for 55.175% of the variance (Factor 1 eigen-
value = 4.967, 41.388% of the variance; Factor 2 eigen-
value = 1.655, 13.789% of the variance). Oblimin rotation 
also confirmed this two-factor solution.
The item loadings from the pattern matrices for the 
Australian and U.K. sample solutions are reported in 
Table 2 and indicate that a two-factor solution, rather than 
a single-factor solution as reported by Innamorati et al. 
(2011) and Chu et al. (2014) most appropriately fits these 
data consistently across the two samples of PCa patients, 
although the order of the factors is reversed from the 
Australian to the U.K. sample. The first factor in the 
Australian sample (and the second factor in the U.K. sam-
ple) may be defined as “Change in Emotional and Somatic 
Functioning” and the second factor in the Australian sam-
ple (first factor in the U.K. sample) may be defined as 
“Depressed Mood.” The interfactor correlation was .691 for 
the Australian sample and .596 for the U.K. sample, both p < 
.001 and accounting for 35.5% and 47.7% of the variance, 
respectively, arguing that these two factors are connected but 
remain discrete. Neither of these two factors was signifi-
cantly correlated with time since diagnosis, present cancer 
status, and past or current treatment in the Australian sample 
but they were both significantly correlated with age (Factor 
1, r = −.226, p = .002; Factor 2, r = −.183, p = .013). For the 
U.K. sample, there were no significant correlations between 
Factors 1 or 2 and time since diagnosis, present cancer 
status, and past or current treatment but Factor 2 was 
significantly correlated with age in this sample (r = −.246, 
p = .004).
As reported in Table 2, the content of the two factors is 
not completely congruent across the two samples, with 
Factor 1 including Decision making and Aggression in 
the Australian sample but not in the U.K. sample, and 
Factor 2 including Burned out and Fatigue for the U.K. 
sample but not for the Australian sample. These minor 
differences reflect those that are common across factor 
structures based on different samples (Tabachnick & 
Fidell, 2007) but, overall, the two factor structures are 
quite similar across the two samples.
Discussion
The presence of a two-factor solution in both these sam-
ples of PCa patients compared with previous reports of a 
single-factor solution in non-PCa men argues for consid-
eration of depression among PCa patients as being unique 
and requiring targeted treatment models that may be dif-
ferent to those applied to non-PCa populations. In addi-
tion, this variability in factor structure between those 
previously reported in non-PCa samples of men (i.e., psy-
chiatric patients: Chu et al., 2014, Innamorati et al., 2011) 
and these two samples of PCa patients may be a possible 
reason for the relatively poor efficacy of standardized 
treatments for depression in this patient group that was 
reported by the two reviews of PCa depression mentioned 
in the “Introduction” section of this article (Chien et al., 
2014; Newby et al., 2015). This kind of variability in fac-
tor structures drawn from different samples has been pre-
viously noted (Tabachnick & Fidell, 2007) and needs to 
Table 2. Factor Structure and Gotland Scale of Male 
Depression (GSMD) Items Loadings for Australian and U.K. 
Patients.
GSMD item content Factor 1 Factor 2
Australian sample  
1. Fatigue .853  
2. Stress .822  
3. Burned out .804  
4. Irritability .779  
5. Anxious .706  
6. Sleep problems .705  
7. Decision making .679  
8. Aggression .585  
9. Alcohol, drugs, hyperactivity .732
10.  Gloomy .671
11.  Behavior changed .595
12. Self-pity .479
U.K. sample  
1. Gloomy .905  
2. Behavior changed .873  
3. Self-pity .772  
4. Aggression .690  
5. Decision making .553  
6. Alcohol, drugs, hyperactivity .540  
7. Burned out .910
8. Fatigue .887
9. Irritability .741
10. Anxious .576
11. Sleep Problems .552
12. Stress .548
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be considered when applying results of studies on a par-
ticular population to diagnosis and treatment planning 
within a different population, particularly across patients 
with an identifiable physical disease (such as PCa) and 
purely psychiatric patients (on which most evidence sup-
porting standardized treatments for depression is based).
Although the same two factors were identified in 
each sample, the variability in loading of those factors 
suggests that U.K. PCa patients may differ from their 
Australian counterparts in the ways that depression mani-
fests itself. Depression in the Australian men was strongly 
characterized by changes in their physiological and emo-
tional states but lesser in their symptoms of depressed 
mood, whereas their U.K. peers exhibited depression 
more strongly characterized by feeling sad and depressed 
with less influence from somatic and emotional changes. 
These differences in factor loadings also suggest that 
similar differences might be present across other national 
or ethnic populations, and further emphasize the need to 
base treatment planning on ideographic data rather than 
assuming that all men experience depression in identical 
ways, regardless of their social and cultural backgrounds 
or disease status.
Limitations of this study include the social and cultural 
nature of the two samples (which may not only be similar 
in many ways but also hold specific differences that may 
have contributed to the different results from the United 
Kingdom and Australia), the use of the GSMD only once, 
and the relatively shallow nature of the background ques-
tionnaire which did not include social and economic data 
which could influence depressive status. Although the ini-
tial analyses conducted on these data did not reveal any 
significant association between male depression and can-
cer status, or past and current treatment, the latter vari-
ables were relatively confined and thus cannot be ruled 
out of contention as possible causal factors in the develop-
ment and severity of male depression. Although self-
reports of depressive symptoms have a sound relationship 
with structured clinical interviews, application of the latter 
could provide valuable information regarding the details 
of depression among these men. Because of the small 
numbers of patients receiving some forms of hormone 
treatments, the presence of different effects from different 
hormone treatments was not examined but is a potentially 
fruitful avenue for further research because of the previ-
ous research which demonstrated depressive effects from 
such treatments (Sharpley, Christie, & Bitsika, 2014).
In summary, assessment of depression in PCa patients 
may benefit from an awareness of the underlying struc-
ture of that depression and how it may manifest as more 
than simply MDD symptoms. Using a standardized MDD-
based treatment model with all PCa patients is less likely 
to be effective than individualized treatment plans based 
on the specific symptom profiles of these patients, and the 
application of the GSMD could provide valuable data for 
provision of personalized treatment for the depression that 
PCa patients experience (Insel, 2013), thus potentially 
increasing the (currently low) efficacy of antidepressant 
interventions with these men. Furthermore, examination 
of the underlying structures of male depression as it is 
experienced by particular disease- and national/cultural 
groups of men may assist in developing more targeted and 
effective treatments for male depression.
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